Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
New England Journal of Medicine.
Times cited: 702
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.
Times cited: 45